WHO ICTRP trial
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, WITH ACTIVE CONTROL, IN PARALLEL…
PER-060-03 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-060-03 |
|---|---|
| Public title | MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, WITH ACTIVE CONTROL, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY AND SAFETY OF VALSARTAN 320 MG COMPARED WITH VALSARTAN 160 MG IN HYPERTENSION PATIENTS |
| Scientific title | MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, WITH ACTIVE CONTROL, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY AND SAFETY OF VALSARTAN 320 MG COMPARED WITH VALSARTAN 160 MG IN HYPERTENSION PATIENTS |
| Primary sponsor | NOVARTIS BIOSCIENSES PERU S.A., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 0 |
| Countries | Spain;Brazil;Peru;United States |
| Conditions | -I10 Essential (primary) hypertension Essential (primary) hypertension;I10 ;Essential (primary) hypertension |
| Interventions | Group name:Valsartan 320 mg Type of group;1 N° of participants:1618 Intervention(s) description:Valsartan 160 mg will be administered for 4 weeks, then aleatorized and Valsartan 320 mg administered for 4 weeks. Group name:Valsartan 160 mg… |
| Registration date | Nov 24, 2003 |
| Target size | 172 |
| Secondary IDs | NCT00241137 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: